Otsuka strikes licensing deal of diabetes therapy
Otsuka Pharmaceutical has licensed the Japanese rights to Bristol-Myers Squibb's saxagliptin, being studied for the treatment of Type 2 diabetes. BMS gets an upfront payment and a schedule of milestones. Saxagliptin, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) inhibitor currently in Phase III development in the United States and Europe.
- here's the report on the deal from MedicalNewsToday
Related Articles:
Cornelius get big payday for BMS temp job. Report
Bristol-Myers agrees to pay $499M to settle probes. Report
Be the first to comment
More stories about Phase III milestones Type 2 Diabetes upfront payment lawsuits Bristol-Myers Squibb
Comments
By smjacob | Posted 6:32pm | August 5, 2007
I can see two sides to this story. One that is good and one bad. The good one is the fact that the researches concerning saxagliptin will probably get accelerated by the Japanese technology that will be involved in these researches. Many people probably anctiously await this promise drug to appear in pharmacies and online pharmacies alike. The bad side of the story is the part where Otsuka Pharmaceutical has exclusive wrights. And from exclusive wrights, nothing good has ever come out for the average buyer. Sure it's convenient for the Bristol-Myers Squibb company, but I don't believe in the exclusive wrights idea.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
